Intradermal immunization improves protective efficacy of a novel TB vaccine candidate
Abstract We have developed the Mycobacterium tuberculosis (Mtb) fusion protein (ID83), which contains the three Mtb proteins Rv1813, Rv3620 and Rv2608. We evaluated the immunogenicity and protective efficacy of ID83 in combination with several emulsion-formulated toll-like receptor agonists. The ID8...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2009-05, Vol.27 (23), p.3063-3071 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3071 |
|---|---|
| container_issue | 23 |
| container_start_page | 3063 |
| container_title | Vaccine |
| container_volume | 27 |
| creator | Baldwin, Susan L Bertholet, Sylvie Kahn, Maria Zharkikh, Irina Ireton, Gregory C Vedvick, Thomas S Reed, Steven G Coler, Rhea N |
| description | Abstract We have developed the Mycobacterium tuberculosis (Mtb) fusion protein (ID83), which contains the three Mtb proteins Rv1813, Rv3620 and Rv2608. We evaluated the immunogenicity and protective efficacy of ID83 in combination with several emulsion-formulated toll-like receptor agonists. The ID83 subunit vaccines containing synthetic TLR4 or TLR9 agonists generated a T helper-1 immune response and protected mice against challenge with Mtb regardless of route. The ID83 vaccine formulated with gardiquimod (a TLR7 agonist) also resulted in a protective response when administered intradermally, whereas the same vaccine given subcutaneously failed to provide protection. This highlights the need to explore different routes of immunization based on the adjuvant formulations used. |
| doi_str_mv | 10.1016/j.vaccine.2009.03.018 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2743149</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0264410X09004095</els_id><sourcerecordid>67226965</sourcerecordid><originalsourceid>FETCH-LOGICAL-c609t-b475ab4f406f3271ee773974505f5cbb4c4134aa0885c108f175b9bf4dcf77f63</originalsourceid><addsrcrecordid>eNqFkk1v1DAQhi0EomXhJ4AiIbjtMv6K40sRVHxUqsSBVuJmOc4YvCTO1s6utPx6vNqohV56Gll-5tU78w4hLymsKND63Xq1s86FiCsGoFfAV0CbR-SUNoovmaTNY3IKrBZLQeHHCXmW8xoAJKf6KTmhWrBGMzgl1xdxSrbDNNi-CsOwjeGPncIYy2OTxh3mqpQJ3RR2WKH3wVm3r0Zf2SqW7766-ljNTipnYxc6O-Fz8sTbPuOLuS7I9edPV-dfl5ffvlycf7hcuhr0tGyFkrYVXkDtOVMUUSmulZAgvXRtK5ygXFgLTSMdhcZTJVvdetE5r5Sv-YKcHXU323bAzuFhmN5sUhhs2pvRBvP_Twy_zM9xZ5gSnApdBN7OAmm82WKezBCyw763EcdtNrVirNa1fBBkILVUxf6CvL4HrsdtimULhta0aYqWEIWSR8qlMeeE_tYzBXPI16zNvFVzyNcANyXf0vfq34HvuuZAC_BmBmx2tvfJRhfyLceoLOqMF-79kcMSzy5gMtkFjA67kErYphvDg1bO7im4PsRyHv1v3GO-m9pkZsB8Pxzj4RZBAwjQkv8FNoTb7g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1618865344</pqid></control><display><type>article</type><title>Intradermal immunization improves protective efficacy of a novel TB vaccine candidate</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Baldwin, Susan L ; Bertholet, Sylvie ; Kahn, Maria ; Zharkikh, Irina ; Ireton, Gregory C ; Vedvick, Thomas S ; Reed, Steven G ; Coler, Rhea N</creator><creatorcontrib>Baldwin, Susan L ; Bertholet, Sylvie ; Kahn, Maria ; Zharkikh, Irina ; Ireton, Gregory C ; Vedvick, Thomas S ; Reed, Steven G ; Coler, Rhea N</creatorcontrib><description>Abstract We have developed the Mycobacterium tuberculosis (Mtb) fusion protein (ID83), which contains the three Mtb proteins Rv1813, Rv3620 and Rv2608. We evaluated the immunogenicity and protective efficacy of ID83 in combination with several emulsion-formulated toll-like receptor agonists. The ID83 subunit vaccines containing synthetic TLR4 or TLR9 agonists generated a T helper-1 immune response and protected mice against challenge with Mtb regardless of route. The ID83 vaccine formulated with gardiquimod (a TLR7 agonist) also resulted in a protective response when administered intradermally, whereas the same vaccine given subcutaneously failed to provide protection. This highlights the need to explore different routes of immunization based on the adjuvant formulations used.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2009.03.018</identifier><identifier>PMID: 19428920</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Adjuvants, Immunologic - administration & dosage ; Allergy and Immunology ; Animals ; Applied microbiology ; Bacteriology ; Biological and medical sciences ; Cloning ; Deoxyribonucleic acid ; DNA ; Female ; Fundamental and applied biological sciences. Psychology ; Humans ; Immune response ; Immunity, Cellular ; Immunization ; Immunogenicity ; Infections ; Injections, Intradermal ; Injections, Subcutaneous ; Ligands ; Mice ; Microbiology ; Miscellaneous ; Mycobacterium tuberculosis ; Mycobacterium tuberculosis - immunology ; Plasmids ; Proteins ; Subunit vaccine ; TLR agonists ; Toll-Like Receptor 4 - agonists ; Toll-Like Receptor 7 - agonists ; Toll-Like Receptor 9 - agonists ; Tuberculosis ; Tuberculosis Vaccines - administration & dosage ; Tuberculosis Vaccines - immunology ; Tuberculosis, Pulmonary - immunology ; Tuberculosis, Pulmonary - prevention & control ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, Subunit - administration & dosage ; Vaccines, Subunit - immunology ; Viral Proteins - immunology</subject><ispartof>Vaccine, 2009-05, Vol.27 (23), p.3063-3071</ispartof><rights>Elsevier Ltd</rights><rights>2009 Elsevier Ltd</rights><rights>2009 INIST-CNRS</rights><rights>Copyright Elsevier Limited May 18, 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c609t-b475ab4f406f3271ee773974505f5cbb4c4134aa0885c108f175b9bf4dcf77f63</citedby><cites>FETCH-LOGICAL-c609t-b475ab4f406f3271ee773974505f5cbb4c4134aa0885c108f175b9bf4dcf77f63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1618865344?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,780,784,885,3548,27922,27923,45993,64383,64385,64387,72239</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21510123$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19428920$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baldwin, Susan L</creatorcontrib><creatorcontrib>Bertholet, Sylvie</creatorcontrib><creatorcontrib>Kahn, Maria</creatorcontrib><creatorcontrib>Zharkikh, Irina</creatorcontrib><creatorcontrib>Ireton, Gregory C</creatorcontrib><creatorcontrib>Vedvick, Thomas S</creatorcontrib><creatorcontrib>Reed, Steven G</creatorcontrib><creatorcontrib>Coler, Rhea N</creatorcontrib><title>Intradermal immunization improves protective efficacy of a novel TB vaccine candidate</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract We have developed the Mycobacterium tuberculosis (Mtb) fusion protein (ID83), which contains the three Mtb proteins Rv1813, Rv3620 and Rv2608. We evaluated the immunogenicity and protective efficacy of ID83 in combination with several emulsion-formulated toll-like receptor agonists. The ID83 subunit vaccines containing synthetic TLR4 or TLR9 agonists generated a T helper-1 immune response and protected mice against challenge with Mtb regardless of route. The ID83 vaccine formulated with gardiquimod (a TLR7 agonist) also resulted in a protective response when administered intradermally, whereas the same vaccine given subcutaneously failed to provide protection. This highlights the need to explore different routes of immunization based on the adjuvant formulations used.</description><subject>Adjuvants, Immunologic - administration & dosage</subject><subject>Allergy and Immunology</subject><subject>Animals</subject><subject>Applied microbiology</subject><subject>Bacteriology</subject><subject>Biological and medical sciences</subject><subject>Cloning</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immunity, Cellular</subject><subject>Immunization</subject><subject>Immunogenicity</subject><subject>Infections</subject><subject>Injections, Intradermal</subject><subject>Injections, Subcutaneous</subject><subject>Ligands</subject><subject>Mice</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Mycobacterium tuberculosis</subject><subject>Mycobacterium tuberculosis - immunology</subject><subject>Plasmids</subject><subject>Proteins</subject><subject>Subunit vaccine</subject><subject>TLR agonists</subject><subject>Toll-Like Receptor 4 - agonists</subject><subject>Toll-Like Receptor 7 - agonists</subject><subject>Toll-Like Receptor 9 - agonists</subject><subject>Tuberculosis</subject><subject>Tuberculosis Vaccines - administration & dosage</subject><subject>Tuberculosis Vaccines - immunology</subject><subject>Tuberculosis, Pulmonary - immunology</subject><subject>Tuberculosis, Pulmonary - prevention & control</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, Subunit - administration & dosage</subject><subject>Vaccines, Subunit - immunology</subject><subject>Viral Proteins - immunology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkk1v1DAQhi0EomXhJ4AiIbjtMv6K40sRVHxUqsSBVuJmOc4YvCTO1s6utPx6vNqohV56Gll-5tU78w4hLymsKND63Xq1s86FiCsGoFfAV0CbR-SUNoovmaTNY3IKrBZLQeHHCXmW8xoAJKf6KTmhWrBGMzgl1xdxSrbDNNi-CsOwjeGPncIYy2OTxh3mqpQJ3RR2WKH3wVm3r0Zf2SqW7766-ljNTipnYxc6O-Fz8sTbPuOLuS7I9edPV-dfl5ffvlycf7hcuhr0tGyFkrYVXkDtOVMUUSmulZAgvXRtK5ygXFgLTSMdhcZTJVvdetE5r5Sv-YKcHXU323bAzuFhmN5sUhhs2pvRBvP_Twy_zM9xZ5gSnApdBN7OAmm82WKezBCyw763EcdtNrVirNa1fBBkILVUxf6CvL4HrsdtimULhta0aYqWEIWSR8qlMeeE_tYzBXPI16zNvFVzyNcANyXf0vfq34HvuuZAC_BmBmx2tvfJRhfyLceoLOqMF-79kcMSzy5gMtkFjA67kErYphvDg1bO7im4PsRyHv1v3GO-m9pkZsB8Pxzj4RZBAwjQkv8FNoTb7g</recordid><startdate>20090518</startdate><enddate>20090518</enddate><creator>Baldwin, Susan L</creator><creator>Bertholet, Sylvie</creator><creator>Kahn, Maria</creator><creator>Zharkikh, Irina</creator><creator>Ireton, Gregory C</creator><creator>Vedvick, Thomas S</creator><creator>Reed, Steven G</creator><creator>Coler, Rhea N</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20090518</creationdate><title>Intradermal immunization improves protective efficacy of a novel TB vaccine candidate</title><author>Baldwin, Susan L ; Bertholet, Sylvie ; Kahn, Maria ; Zharkikh, Irina ; Ireton, Gregory C ; Vedvick, Thomas S ; Reed, Steven G ; Coler, Rhea N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c609t-b475ab4f406f3271ee773974505f5cbb4c4134aa0885c108f175b9bf4dcf77f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adjuvants, Immunologic - administration & dosage</topic><topic>Allergy and Immunology</topic><topic>Animals</topic><topic>Applied microbiology</topic><topic>Bacteriology</topic><topic>Biological and medical sciences</topic><topic>Cloning</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immunity, Cellular</topic><topic>Immunization</topic><topic>Immunogenicity</topic><topic>Infections</topic><topic>Injections, Intradermal</topic><topic>Injections, Subcutaneous</topic><topic>Ligands</topic><topic>Mice</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Mycobacterium tuberculosis</topic><topic>Mycobacterium tuberculosis - immunology</topic><topic>Plasmids</topic><topic>Proteins</topic><topic>Subunit vaccine</topic><topic>TLR agonists</topic><topic>Toll-Like Receptor 4 - agonists</topic><topic>Toll-Like Receptor 7 - agonists</topic><topic>Toll-Like Receptor 9 - agonists</topic><topic>Tuberculosis</topic><topic>Tuberculosis Vaccines - administration & dosage</topic><topic>Tuberculosis Vaccines - immunology</topic><topic>Tuberculosis, Pulmonary - immunology</topic><topic>Tuberculosis, Pulmonary - prevention & control</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, Subunit - administration & dosage</topic><topic>Vaccines, Subunit - immunology</topic><topic>Viral Proteins - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baldwin, Susan L</creatorcontrib><creatorcontrib>Bertholet, Sylvie</creatorcontrib><creatorcontrib>Kahn, Maria</creatorcontrib><creatorcontrib>Zharkikh, Irina</creatorcontrib><creatorcontrib>Ireton, Gregory C</creatorcontrib><creatorcontrib>Vedvick, Thomas S</creatorcontrib><creatorcontrib>Reed, Steven G</creatorcontrib><creatorcontrib>Coler, Rhea N</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baldwin, Susan L</au><au>Bertholet, Sylvie</au><au>Kahn, Maria</au><au>Zharkikh, Irina</au><au>Ireton, Gregory C</au><au>Vedvick, Thomas S</au><au>Reed, Steven G</au><au>Coler, Rhea N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intradermal immunization improves protective efficacy of a novel TB vaccine candidate</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2009-05-18</date><risdate>2009</risdate><volume>27</volume><issue>23</issue><spage>3063</spage><epage>3071</epage><pages>3063-3071</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Abstract We have developed the Mycobacterium tuberculosis (Mtb) fusion protein (ID83), which contains the three Mtb proteins Rv1813, Rv3620 and Rv2608. We evaluated the immunogenicity and protective efficacy of ID83 in combination with several emulsion-formulated toll-like receptor agonists. The ID83 subunit vaccines containing synthetic TLR4 or TLR9 agonists generated a T helper-1 immune response and protected mice against challenge with Mtb regardless of route. The ID83 vaccine formulated with gardiquimod (a TLR7 agonist) also resulted in a protective response when administered intradermally, whereas the same vaccine given subcutaneously failed to provide protection. This highlights the need to explore different routes of immunization based on the adjuvant formulations used.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>19428920</pmid><doi>10.1016/j.vaccine.2009.03.018</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2009-05, Vol.27 (23), p.3063-3071 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2743149 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | Adjuvants, Immunologic - administration & dosage Allergy and Immunology Animals Applied microbiology Bacteriology Biological and medical sciences Cloning Deoxyribonucleic acid DNA Female Fundamental and applied biological sciences. Psychology Humans Immune response Immunity, Cellular Immunization Immunogenicity Infections Injections, Intradermal Injections, Subcutaneous Ligands Mice Microbiology Miscellaneous Mycobacterium tuberculosis Mycobacterium tuberculosis - immunology Plasmids Proteins Subunit vaccine TLR agonists Toll-Like Receptor 4 - agonists Toll-Like Receptor 7 - agonists Toll-Like Receptor 9 - agonists Tuberculosis Tuberculosis Vaccines - administration & dosage Tuberculosis Vaccines - immunology Tuberculosis, Pulmonary - immunology Tuberculosis, Pulmonary - prevention & control Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Subunit - administration & dosage Vaccines, Subunit - immunology Viral Proteins - immunology |
| title | Intradermal immunization improves protective efficacy of a novel TB vaccine candidate |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T06%3A36%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intradermal%20immunization%20improves%20protective%20efficacy%20of%20a%20novel%20TB%20vaccine%20candidate&rft.jtitle=Vaccine&rft.au=Baldwin,%20Susan%20L&rft.date=2009-05-18&rft.volume=27&rft.issue=23&rft.spage=3063&rft.epage=3071&rft.pages=3063-3071&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2009.03.018&rft_dat=%3Cproquest_pubme%3E67226965%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1618865344&rft_id=info:pmid/19428920&rft_els_id=1_s2_0_S0264410X09004095&rfr_iscdi=true |